Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05684016 · ClinicalTrials.gov registry record · NA
Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM
A NA study, sponsored by George Washington University.
- Completed
- Registry status
- NA
- Development phase
- 75
- Enrollment target
NCT05684016 is a NA study that has completed, run by George Washington University. The registered enrollment target is 75 participants.
The verdict
NCT05684016, a NA study, has completed, sponsored by George Washington University.
- COMPLETED
- Registry status
- NA
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of the research study is to investigate whether the extent and severity of lesions in the brain as measured by special MRI techniques can distinguish between Multiple Sclerosis (MS) patients with or without memory impairment and also between MS patients and age matched healthy controls.
Interventions
- OTHER Physical Examination
- OTHER NeuroQuant
- OTHER Automated Neuropsychological Assessment Matrices
- OTHER EDSS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2013-12 |
| Est. Completion | 2016-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05684016
The ClinicalTrials.gov registry entry for NCT05684016 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is George Washington University, which has 133 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Physical Examination is the first listed.
NCT05684016 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05684016 about?
NCT05684016 is a clinical study titled "Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM". The purpose of the research study is to investigate whether the extent and severity of lesions in the brain as measured by special MRI techniques can distinguish between Multiple Sclerosis (MS) patients with or without memory impairment and also between MS patients and age matched healthy controls.
What is the current status of trial NCT05684016?
This trial is currently completed. It is a NA study. The enrollment target is 75 participants. The study started on 2013-12. Estimated completion is 2016-12.
What interventions are being tested in trial NCT05684016?
The interventions under investigation include: Physical Examination (OTHER), NeuroQuant (OTHER), Automated Neuropsychological Assessment Matrices (OTHER), EDSS (OTHER).
Who is sponsoring clinical trial NCT05684016?
This trial is sponsored by George Washington University, which has 133 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.